Technology | Artificial Intelligence | June 20, 2019

TeraRecon Receives First-of-Kind FDA Determination for Northstar AI Results Explorer

Class I medical device provides physicians way to accept, reject and interact with artificial intelligence-derived radiology findings

TeraRecon Receives FDA Clearance for Northstar AI Results Explorer

June 20, 2019 — Advanced visualization and artificial intelligence (AI) technology provider TeraRecon has successfully completed a U.S. Food and Drug Administration (FDA) regulatory review of its Northstar AI Results Explorer. TeraRecon said the technology and the determination are both firsts-of-kind in the medical imaging industry. Northstar is designed to work alongside the company’s EnvoyAI interoperability platform, which includes FDA-cleared third-party content listed on its EnvoyAI Exchange marketplace.

The Northstar AI Results Explorer provides an engaging physician user experience that can be integrated into the clinical systems already used throughout the health enterprise. Now with full commercial availability, Northstar can provide physicians a way to accept, reject and interact with AI-derived findings. Through the EnvoyAI marketplace, health systems can enter into a single contractual agreement and confidently run algorithms interchangeably, with a single two-hour software installation.

EnvoyAI customers currently have access to more than 80 algorithms with 20 holding regulatory clearances in various global territories.

TeraRecon maintains stringent processes, documentation and quality systems across its design, development and business operations. The FDA has determined that the Northstar AI Results Explorer is exempt from Class II premarket notification requirements, and therefore is considered a Class I medical device alongside their existing Class I EnvoyAI platform.

TeraRecon technologies including the EnvoyAI platform, TeraRecon Northstar AI Results Explorer and its flagship iNtuition advanced visualization solution, will be on display at the Society for Imaging Informatics in Medicine (SIIM) conference, June 26-28 in Aurora, Colo.

For more information: www.terarecon.com

Related Content

he U.S. Food and Drug Administration (FDA) has issued a final order to reclassify medical image analyzers applied to mammography breast cancer, ultrasound breast lesions, radiograph lung nodules and radiograph dental caries detection, postamendments class III devices (regulated under product code MYN), into class II (special controls), subject to premarket notification

Image courtesy of iCAD

News | Computer-Aided Detection Software | January 22, 2020
January 22, 2020 — The U.S.
Medical imaging technology company Oxipit announced partnership with Swiss medical distribution company Healthcare Konnect to bring ChestEye AI imaging suite to healthcare institutions in Nigeria
News | Artificial Intelligence | January 22, 2020
January 22, 2020 — Medical imaging technology company Oxipit ann
Hitachi Healthcare Americas announced that it will create a new dedicated research and development facility within its North American headquarters facility in Twinsburg, Ohio
News | Radiology Business | January 21, 2020
January 21, 2020 — Hitachi Healthcare Americas announced that it will create a new dedicated research and development
Sponsored Content | Videos | Enterprise Imaging | January 20, 2020
GE Healthcare's iCenter is a cloud-based management software that provides 24/7 visibility to customers' visual and o
This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.   #RSNA #

This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.

Feature | RSNA | January 20, 2020 | Dave Fornell, Editor
Here are images of some of the newest new medical imaging technologies displayed on the expo floor at the ...
Carestream’s X-ray digital tomosynthesis functionality creates three-dimensional datasets from digital radiography (DR) that can be scrolled through similar to computed tomography (CT) imaging. It received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in January 2020. Digital tomosynthesis uses a single sweep of X-ray exposures and streamlines operator workflow by separating the process of DT exposure acquisition from image volume formation.
News | Digital Radiography (DR) | January 15, 2020
January 15, 2020 — Carestream’s X-ray digital tomosynthesis (DT) functionality, which creates three-dimensional datas
Konica Minolta Business Solutions, U.S.A., Inc. (Konica Minolta) announced its status as a Google Cloud Premier Partner.
News | Archive Cloud Storage | January 14, 2020
January 14, 2020 — ...
Videos | RSNA | January 13, 2020
ITN Editor Dave Fornell takes a tour of some of the most innovative new medical imaging technologies displayed on the